Medical oncologist Dr Philipp Ivanyi joined us at ESMO 2023 to share his thoughts on the latest precision oncology data to emerge from the congress and the possible impact on clinical practice. 

Clinical Takeaways

Cancer of unknown primary

  • CUPISCO: In patients with newly diagnosed, unfavourable, non-squamous CUP that responded to induction CTX, CGP with MGT improved PFS, thereby supporting a precision oncology approach in these patients
  • CUP-ONE: CTID molecular-expression classifier demonstrated similar performance overall to specialist C-IHC
  • Fudan CUP-001: Site-specific treatment guided by the approved 90-gene expression assay resulted in more therapy options, and significantly improved PFS with favourable OS vs empirical chemotherapy in patients with de novo CUP

Diagnostic

  • ARCAGEN: Molecular profiling of rare cancers identified many targetable alterations, and should be more routinely performed

Treatment

  • DESTINY-PanTumor01 (DPT-01): In heavily pretreated patients with limited treatment options, T-DXd demonstrated encouraging anticancer activity and long DoR across multiple tumour types with HER2m and a range of HER2 expression levels
  • LIBRETTO-531: First-line selpercatinib prolonged PFS, improved ORR, and achieved a better OS vs MKIs, and should now be considered the preferred first-line standard of care for patients with advanced RET-mutant MTC

 

  • Help physicians translate the latest Precision Oncology data from ESMO 2023 into clinical practice.

Dr Ivanyi is the Assistant Medical Director Hematology, Oncology, Hemostasis, Stem Cell Transplantation (Palliative Care) at the Hanover Medical School. He is also Head of the Clinical Trial Unit for Medical Oncology

Dr Ivanyi also serves as:

  • Steering Committee and Spokesman, Immune Cooperative Oncology Group, Comporehensive Cancer Center, Claudia von Schelling Center (CCC-H)
  • Board Member, Clinical Trial Steering Committee, CCC-H
  • Spokesman Interdisciplinary Working Group Kidney Cancer, Germany Cancer Society (IAGN-DKG)

His research interests include clinical and experimental Research in Urogenital Cancer, Head and Neck Cancer, Sarcoma, Rare Cancers, Targeted Therapies. He has >80 SCI Publication and has a depth of experience in >50 Clinical Trials Phase I – IV (PI and Country Lead).

Dr Philipp Ivanyi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AIM, AIO, Apogepha, Astella, Astra Zeneca, Bayer, BMS, ClinSol, Deciphera, Deutsche Gesellschaft für Thoraxchirurgie, DKG-Onkoweb, EISAI, EMD-Serono, EUSA, FoFM, GSK, Id-Institut, Ipsen (Europe), Lilly, MedKom, Metaplan, MedWiss, Merck Serono (Global), MSD, MTE-Academy, New Concept Oncology, Niedersächsische Krebsgesellschaft, Novartis, Onkowissen-tv.de, Pharma Mare, Pfizer, Roche, Schmitz-Communikation, Solution Academy,Stiftung Immunonkologie, StreamedUP!, ThinkWired!, Vivantis and Wilhelm Sander Stiftung.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

publication Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
video Video
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
interactive-patient-case Interactive patient case
Oncology 
NTRK fusion testing and treatment in paediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
interactive-patient-case Interactive patient case
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED